On November 29th, China's Tumor Precision Medical Enterprise Idea announced that the submitted New Drug Research Application (IND) has been approved by the US Food and Drug Administration (FDA) for clinical research in the United States.
KN035 is a new generation of PD-L1 antibody jointly developed by Idea Di and Corning Jerry, which is significantly different from the PD1/PDL1 antibody currently available and under investigation. KN035 is currently the only antibody in the world that has been clinically developed for subcutaneous injection of tumor immunotherapy.
Idea Di has 3DMed as the company's English name, and behind this is the diagnostic (Diagnostics), Data (Data), Drug (Drug) precision medical "integration and treatment integration" closed-loop mode. However, Xiong Lei, the chairman of Ideas Precision Medical Group and the founder of Idea Di, kept a clear understanding of precision medicine. He told Shell Office that companies engaged in NGS (high-throughput sequencing) are particularly numerous, using pure NGS as a precise diagnosis, and even taking accurate diagnosis as precision medicine. This is the biggest bubble.
Recently, Xiong Lei mentioned the solution of precision medical treatment at the 6th Bio4P Precision Medical Innovation Forum and 2016 China Medical Innovation and Entrepreneurship Conference hosted by Shell Society, director of the Peking University Medical Department and Academician Zhan Qimin of the Chinese Academy of Engineering. The integrated business model of diagnosis and treatment with accurate diagnostic techniques and data support for drug development will play an important role in achieving a closed loop of precision medicine.
Talk about the integration of diagnosis and treatment: find the most accurate drug use population through the diagnosis business
Shell Society: Idea Di proposes a business model for integrated diagnosis and treatment, and uses precise diagnostic techniques and data to support drug development. How does this model work on the development of new drugs for Ideas?
Xiong Lei: The strategy of integrated diagnosis and treatment will greatly enhance the efficiency of new drug research and development. The combination of diagnosis and new drug clinical trials can assist in the precise development of drugs, accelerate the evaluation, and achieve the ultimate personalized drug promotion.
In the field of cancer, for a company that only diagnoses, its value in the precision medical industry chain is limited, because the late peer diagnosis often faces the situation of too many mutations and too few drugs. For a company that only engages in drug development, it lacks (targeted) pre-clinical development of personalized drugs, clinical trials guided by markers, and important marker diagnostic development platforms and diagnostic data during the marketing process. There are still huge risks. Therefore, in the business model of tumor precision medical treatment, it is necessary to realize the integration of diagnosis and treatment.
Peer diagnosis is the basis of individualized diagnosis and treatment. Peer diagnosis means that when using a drug, taking into account the individual differences of the patient, it is necessary to first detect the type of biological indicator of the lesion site. Peer diagnosis is an indispensable role in the entire cancer medical industry chain, but it is still a supportive role, but this auxiliary role plays a very important role in the treatment.
For patients, patients must be diagnosed before using a targeted, targeted drug. This is because the cost of a targeted drug is generally more expensive, and accurate diagnosis can avoid the extra expense of misuse. On the other hand, erroneous medication can also delay the patient's optimal treatment window, and even severely threaten the patient's life.
Lysine Aspirin,Indomethacin Capsules,Analgesic & Antipyretic,Diclofenac Injection Uses
NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com